AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7483792
Drug: TBE vaccine
RxNorm normalized name: TBE vaccine
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBE vaccine plus TBE immunoglobulin on day 0 plus TBE vaccine on day 28
Trial: 1836920
Drug: Recombinant yeast-derived
RxNorm normalized name: YEAST CELL,LIVE DERIVATIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant yeast-derived hepatitis B vaccine
Trial: 6123342
Drug: Prazosin (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (not specified dosage)
Trial: 21674132
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation with warfarin
Trial: 21674132
Drug: Antiplatelet agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agents (aspirin or thienopyridine)
Trial: 12546741
Drug: Steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid treatment (hydrocortisone sodium succinate at 150 mg to 200 mg daily)
Trial: 12546741
Drug: Conventional supporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional supporting treatment
Trial: 12546741
Drug: Steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid treatment (hydrocortisone sodium succinate)
Trial: 8883116
Drug: Alfacalcidol treatment
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol treatment (0.25 micrograms twice daily)
Trial: 8883116
Drug: Vitamin D2
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin D2 supplementation (500‐1000 units daily)
Trial: 3919550
Drug: Molsidomine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine (8 to 12 mg orally)
Trial: 3919550
Drug: Molsidomine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine (8 to 12 mg intravenously)
Trial: 3919550
Drug: Molsidomine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine (12 mg)
Trial: 3919550
Drug: Molsidomine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine (12 mg intravenously)
Trial: 3919550
Drug: Nitroglycerin (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (1.6 mg sublingually)
Trial: 29397899
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day sodium benzoate
Trial: 29397899
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day sodium benzoate
Trial: 27659931
Drug: Neutral-pH, low-GDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral-pH, low-GDP peritoneal dialysis solution (balance)
Trial: 20844595
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg s.c. every other week for 4 weeks
Trial: 15917949
Drug: FTY720 (0.25‐2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY720 (0.25‐2.5 mg/day)
Trial: 15917949
Drug: Mofetil mycophenolate
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mofetil mycophenolate (2 mg/day)
Trial: 10511062
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg clarithromycin twice a day for 3 days, followed by 20 mg omeprazole
Trial: 27993589
Drug: Fixed-combination travoprost
RxNorm normalized name: Travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed-combination travoprost 0.004%/timolol 0.5% (TTFC)
Trial: 25548798
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise (30 minutes twice a week)
Trial: 24802019
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg FTC capsules alone (Group A)
Trial: 24802019
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg FTC combined with 300 mg TDF tablets (Group B)
Trial: 24802019
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg FTC plus 300 mg TDF with a high-fat diet (Group C)
Trial: 24802019
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of 200 mg FTC capsules (Group D)
Trial: 24802019
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of 200 mg FTC combined with 300 mg TDF tablets (Group E)
Trial: 24802019
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of 200 mg FTC plus 300 mg TDF with a high-fat diet (Group F)
Trial: 2544640
Drug: Bupivacaine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (5 mg/ml)
Trial: 2544640
Drug: Lidocaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (20 mg/ml)
Trial: 20819550
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of gatifloxacin ophthalmic gel vs solution
Trial: 9352758
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine 0.0625% + fentanyl 3.3 micrograms/ml infusion (Group EPI)
Trial: 9352758
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous morphine analgesia (Group PCA)
Trial: 3536108
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nifedipine eight hourly for three weeks
Trial: 29848361
Drug: Febuxostat IR
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat IR 40 mg
Trial: 29848361
Drug: Febuxostat IR
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat IR 80 mg
Trial: 29848361
Drug: Febuxostat XR
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat XR 40 mg
Trial: 29848361
Drug: Febuxostat XR
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat XR 80 mg
Trial: 26210304
Drug: Continuous defocused
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous defocused CO2 laser treatment
Trial: 26210304
Drug: Symptomatic conservative
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic conservative treatment (oral salve containing lidocaine hydrochloride or systemic diclofenac)
Trial: 23041585
Drug: Flat dosing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flat dosing of carboplatin (Arm A)
Trial: 23041585
Drug: Intrapatient dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapatient dose escalation of carboplatin (Arm B)
Trial: 19458031
Drug: Plant sterol
RxNorm normalized name: plant sterol complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol esters (2.5 g/d)
Trial: 19458031
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol esters (2.5 g/d)
Trial: 7738618
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy with fadrozole
Trial: 7323140
Drug: Chlorpromazine (CPZ)
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (CPZ) at four different doses
Trial: 31543299
Drug: ICG-diode laser
RxNorm normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICG-diode laser treatment (PTT group)
Trial: 30390647
Drug: Early mass
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early mass drug administration (MDA) consisting of 3 rounds of a 3-day course of dihydroartemisinin-piperaquine plus a single low dose of primaquine.
Trial: 30390647
Drug: Deferred mass
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred mass drug administration (control group).
Trial: 30390647
Drug: Early mass
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early mass drug administration (MDA).
Trial: 26244387
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with baseline viral load at least 100,000 copies/ml
Trial: 18449593
Drug: Trimebutine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimebutine (200 mg)
Trial: 16513579
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg and hydrochlorothiazide (HCTZ) 12.5 mg
Trial: 14510746
Drug: Raftilin HP
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raftilin HP (5 or 10 g)
Trial: 11014404
Drug: Loperamide (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (16 mg) with quinidine (600 mg)
Trial: 11014404
Drug: Loperamide (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (16 mg) alone
Trial: 9001833
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 mL of normal saline)
Trial: 6601560
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of 4-aminobenzoic acid (PAB) with meals (240 mg/day)
Trial: 6601560
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 80 mg of PAB
Trial: 6601560
Drug: Various doses
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various doses of PAB divided throughout the day
Trial: 6601560
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of PAB with meals
Trial: 28980294
Drug: Intravenous N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous N-acetylcysteine (NAC) infusion (50 mg/kg) after induction of anaesthesia, with two additional doses on postoperative days 1 and 2.
Trial: 28980294
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (placebo) administered during the same time interval as NAC.
Trial: 27981301
Drug: Oral vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vancomycin (125 mg, four times a day) for 12 weeks
Trial: 25642527
Drug: Patient-centred structured
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-centred structured assessment linked to evidence-based treatment algorithms in 15 intervention services.
Trial: 23726776
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy / Interpersonal therapy
Trial: 11122033
Drug: Topical tazarotene
RxNorm normalized name: tazarotene Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tazarotene gel with narrowband UVB (311 nm)
Trial: 11122033
Drug: Topical calcipotriol
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical calcipotriol with narrowband UVB (311 nm)
Trial: 9382235
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine with 0.1 mg of clonidine
Trial: 9382235
Drug: Regular intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular intramuscular morphine
Trial: 1397240
Drug: Induction and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction and consolidation chemotherapy with weekly parenteral vincristine, adriamycin, l‐asparaginase and daily oral prednisone (VAAP)
Trial: 1397240
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy for 3 years consisting of daily 6‐mercaptopurine, weekly methotrexate, and monthly intrathecal chemotherapy
Trial: 1397240
Drug: Drug intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug intensification comprising either vincristine, adriamycin and l‐asparaginase (VAA) or cyclophosphamide, vincristine, cytosine arabinoside and prednisone (COAP)
Trial: 31601541
Drug: Four doses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four doses of NYVAC vector and gp120 Env protein (T2)
Trial: 31601541
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of DNA vector followed by two doses of NYVAC vector and gp120 Env protein (T3)
Trial: 31601541
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of DNA vector and gp120 Env protein followed by two doses of NYVAC vector and gp120 Env protein (T4)
Trial: 27314448
Drug: Intraperitoneal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intraperitoneal bevacizumab (400 mg absolute)
Trial: 20602795
Drug: Bimanual occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimanual occupational therapy
Trial: 17580357
Drug: duloxetine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: duloxetine 80 mg/day
Trial: 15644669
Drug: 7.5% saline/6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% saline/6% dextran solution (HSD)
Trial: 12064330
Drug: 0.8 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg/d phylloquinone for 12 days
Trial: 12064330
Drug: 2.0 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/d phylloquinone for 12 days
Trial: 12064330
Drug: 4.0 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 mg/d phylloquinone for 12 days
Trial: 7845827
Drug: Propafenone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (600 mg)
Trial: 7845827
Drug: Flecainide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (300 mg)
Trial: 20177030
Drug: HEC-90 (trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC-90 (trastuzumab plus cyclophosphamide and epirubicin 90 mg/m2)
Trial: 20177030
Drug: HEC-60 (trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC-60 (trastuzumab plus cyclophosphamide and epirubicin 60 mg/m2)
Trial: 20177030
Drug: EC-90 (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC-90 (epirubicin 90 mg/m2 and cyclophosphamide)
Trial: 10386423
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion at 'renal dose' (2.5‐4.0 microg/kg per min) for 48 hours
Trial: 8814216
Drug: 495 mg
RxNorm normalized name: calcium carbonate 495 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 495 mg daily AA supplement (high AA group)
Trial: 8814216
Drug: 5 mg/d
RxNorm normalized name: Arixtra 5 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/d of AA (low AA group)
Trial: 8814216
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg daily doses of hexadeuterated RRR‐alpha‐tocopherol acetate (d6‐alphaT)
Trial: 1481636
Drug: Intracutaneous sterile
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneous sterile water injections
Trial: 29186416
Drug: Neuropeptide Y
RxNorm normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuropeptide Y 1.4 mg
Trial: 29186416
Drug: Neuropeptide Y
RxNorm normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuropeptide Y 2.8 mg
Trial: 29186416
Drug: Neuropeptide Y
RxNorm normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuropeptide Y 4.6 mg
Trial: 29186416
Drug: Neuropeptide Y
RxNorm normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuropeptide Y 6.8 mg
Trial: 29186416
Drug: Neuropeptide Y
RxNorm normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuropeptide Y 9.6 mg
Trial: 16286671
Drug: Astaxanthin (BioAstin;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin (BioAstin; 1732 mg safflower oil; haematococcus algae extract [contains 4 mg astaxanthin and 480 mg lutein], n = 10)
Trial: 16286671
Drug: Placebo (1732
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1732 mg safflower oil, n = 10)
Trial: 6820075
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid solution containing 3.6% total nitrogen as arginine
Trial: 6820075
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid solution containing 10.4% total nitrogen as arginine
Trial: 31463257
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg daily)
Trial: 26821779
Drug: Low-magnitude mechanical
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-magnitude mechanical stimulation (LMMS) - 10 minutes daily exposure at 30 Hz frequency, 0.3 g peak-to-peak acceleration.
Trial: 26821779
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control group) - 10 minutes daily exposure, no mechanical stimulation.
Trial: 20231743
Drug: Menthol counterirritant
RxNorm normalized name: Menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menthol counterirritant (2 ml applied to anterior knee)
Trial: 20231743
Drug: Sham counterirritant
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham counterirritant (2 ml applied to anterior knee)
Trial: 18683490
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral probucol (250 mg daily)
Trial: 18683490
Drug: Probucol therapy
RxNorm normalized name: Probucol
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probucol therapy for 7 days before and 6 months after coronary angioplasty
Trial: 2089092
Drug: MDL 72.974A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDL 72.974A (0.1-12 mg)
Trial: 848665
Drug: Intraluminal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraluminal administration of 5-fluorouracil (5-FU)
Trial: 848665
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 5-fluorouracil (5-FU)
Trial: 848665
Drug: Intramural administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramural administration of 5-fluorouracil (5-FU)
Trial: 848665
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) therapy (general)
Trial: 28449281
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg varenicline
Trial: 25847552
Drug: OMT+medication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMT+medication therapy
Trial: 23818409
Drug: Modified constraint‐induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint‐induced movement therapy (kid‐CIMT)
Trial: 17323661
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.1 ml/kg (Group NS)
Trial: 17323661
Drug: Lignocaine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 1.5 mg/kg (Group L)
Trial: 9591761
Drug: abciximab (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abciximab (0.25 mg/kg bolus and 12-hour infusion of 10 microg/min, EPIC regimen)
Trial: 9591761
Drug: abciximab (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abciximab (0.25 mg/kg bolus and 12-hour infusion of 0.125 microg x kg(‐1) x min(‐1), EPILOG regimen)
Trial: 8201150
Drug: KC‐764 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KC‐764 10 mg/day
Trial: 8201150
Drug: KC‐764 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KC‐764 20 mg/day
Trial: 8201150
Drug: KC‐764 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KC‐764 40 mg/day
Trial: 8201150
Drug: KC‐764 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KC‐764 (all doses)
Trial: 3310633
Drug: Sucralfate 2
RxNorm normalized name: sucralfate 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 2 g at night
Trial: 30742513
Drug: 2-hour workshop
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-hour workshop on compression therapy (n = 14)
Trial: 10516941
Drug: Ciclesonide nasal
RxNorm normalized name: ciclesonide nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide nasal spray (200 micrograms per nostril)
Trial: 31116017
Drug: Computer-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-based cognitive behavioral therapy